HeartForce has successfully integrated its advanced EMR-Score algorithm portfolio into the CardioClin platform. This move positions CardioClin as the leading early detection tool for coronary artery disease (CAD), primarily assisting physicians and nurses. We are now ready to seek regulatory approvals from Health Canada, and the FDA. The improved EMR-Score uses both qualitative and quantitative… Continue reading Integration of the EMR-Score into the CardioClin Platform
Author: Nicholas Jessel
Design Freeze for CardioClin 3.0
The recent design freeze for CardioClin marks an important milestone for HeartForce in advancing towards commercialization and regulatory approval. Following extensive clinical research involving over 4,000 patients and valuable input from healthcare experts, the latest iteration of CardioClin has undergone meticulous redesign to improve its user-friendliness and features. Additionally, our exclusive core technology has been… Continue reading Design Freeze for CardioClin 3.0
HeartForce Commences Production of 200 CardioClin’s for Testing Purposes
The manufacturing process for 200 CardioClin devices for testing purposes has commenced. HeartForce has started producing 200 units of the CardioClin version 3.0, which features a new compact and seamless design. These devices will be sent to key opinion leaders in Canada, Germany, and Switzerland. Each device will come with 20 patches and an additional… Continue reading HeartForce Commences Production of 200 CardioClin’s for Testing Purposes
Completion of Statistical Analysis for Cost-Effectiveness report
HeartForce has finalized its analysis on the cost-effectiveness of the CardioClin within the Canadian healthcare system. By analyzing billing codes under the Ontario Health Insurance Plan (OHIP), we investigated the devices utilized in the diagnostic pathway for Coronary Artery Disease (CAD). This pathway encompasses both the bulk of individuals diagnosed with CAD and, those with… Continue reading Completion of Statistical Analysis for Cost-Effectiveness report
EMR Score Introduced at the Computing in Cardiology Conference
HeartForce introduced the Electromechanical Risk (EMR) Score at the prestigious CinC2023 conference held in Atlanta. Computing in Cardiology Conference, a globally recognized scientific symposium, provides a platform for experts in the fields of medicine, physics, engineering, and computer science to disseminate their cutting-edge research in clinical cardiology and cardiovascular physiology. The EMR Score’s debut at… Continue reading EMR Score Introduced at the Computing in Cardiology Conference
HeartForce presents CardioClin 3.0
Hearforce’s design team optimized the next generation of CardioClin which featured a more ergonomic shape and improved usability. The narrower shape allows a better fit for both female and male users. The small disposable electrode patch lets the sensor be easy to apply and sanitize.
Finalization of HeartForce proprietary EMR-Score-Algorithm
HeartForce has developed the Electromechanical Risk (EMR) Score, a groundbreaking AI-powered tool for precise cardiac risk assessment in coronary artery disease (CAD) screening. Leveraging seismocardiography (SCG) data and clinical variables, the EMR Score offers a non-invasive, data-driven approach to screen CAD risk. The use of SCG enhances patient comfort and convenience during screening. The EMR… Continue reading Finalization of HeartForce proprietary EMR-Score-Algorithm
Finalizing AFib Algorithm
Heartforce’s Afib detection algorithm was tested on a large database of 84k cases with an accuracy equivalent to current FDA approved algorithms. Afib detection will be deployed on future CardioClin and CardioPro products and will be ready for Health Canada and FDA submissions.
HeartForce starts Phase 1 of Verification Study in Uzbekistan
HeartForce has embarked on Phase 1 of a Verification Study in Uzbekistan. This significant undertaking follows the successful development of the EMR Score in a prior study. In this new phase, HeartForce is in the process of acquiring a comprehensive verification database, meticulously designed to closely resemble the characteristics of the actual target population. This… Continue reading HeartForce starts Phase 1 of Verification Study in Uzbekistan
HeartForce files new provisional patent in the US
HeartForce filed a patent application in the United States for monitoring patients after coronary angioplasty. The provisional patent was assigned the application number U.S. 63/459960. Meanwhile, the company will be conducting a one-year clinical study through the monitoring patients pre and post stent surgery
Need to get in touch with the team? We’re all ears.
Contact us today.
This website (“Web Site”) is offered to you by HeartForce Medical Inc. (HeartForce), Vancouver, BC, Canada.
The following Terms of Use govern your access and use of this Web Site and its service. Also, specific terms and conditions may apply to specific content, data, materials, or information contained on or available through this Web Site (the “Content”) and to specific content, data, materials, or information you may upload, submit and/or publish to the Web Site (“User Content”) or transactions concluded through this Web Site.
The following Terms of Use govern your access and use of this Web Site and its service. Also, specific terms and conditions may apply to specific content, data, materials, or information contained on or available through this Web Site (the “Content”) and to specific content, data, materials, or information you may upload, submit and/or publish to the Web Site (“User Content”) or transactions concluded through this Web Site.